Sustainability

Introduction and Purpose

Our mission is to create first-in-class drugs that improve the quality of life of patients, especially in the field of oncology. The values and principles of the company's operation are set out in our Code of Ethical Conduct. Our key values are:

• Integrity
• Collaboration
• Transparency
• Scientific Excellence
• Development
• Discipline

Our approach to social, regulatory and environmental issues stems directly from these values and the mission we pursue. We strive to combine scientific progress with responsible business practices that benefit patients, employees, communities, investors and the environment.

👥 Social Issues (S)

Our social activities are based on the mission and values that we implement in our daily work, responding to the needs of key stakeholders: patients, employees, doctors and the local community.

Patients

Patients are at the heart of our activities. We focus on diseases of high social importance, especially in the area of oncology. We strive to improve the quality of life of patients through innovative therapies. The production of chemical drugs enables their wide availability, which is crucial in the context of the fight against cancer.

Employees and employee rights

We care about the well-being of our employees, treating them as a key element of the company's success. We support their professional development by offering an environment conducive to engagement, mental and physical health. We also provide an incentive program covering all levels of the organization.

Equal opportunities

We are committed to ensuring that all employees are treated equally, regardless of gender, nationality or religion. We comply with our "Anti-discrimination policy", the aim of which is to ensure equal opportunities in every aspect of employment. A diverse team enriches our organization with an international perspective, and the participation of women and men in management positions is similar.

Local community

We are aware of the support we have received in the form of public grants and we are involved in the development of the community in which we operate. We create jobs, support the development of the biotechnology sector and engage in charitable initiatives supporting people in need.

Physicians

Cooperation with doctors at the stage of drug development is crucial for us. Thanks to their experience in treating patients, we develop therapies that meet real clinical needs, providing physicians with effective and convenient therapeutic solutions.

Clinical ethics

All of our clinical research activities comply with international ethical standards and the principles of Good Clinical Practice (GCP). We are committed to full transparency and honesty in the research process, ensuring patient safety and maintaining the highest ethical standards. We cooperate with the relevant regulatory authorities to ensure that our therapies are safe, effective and fully compliant with legal regulations.

📊 Supervisory Matters (G)

We conduct our business in a fair, transparent and responsible manner towards all stakeholder groups: shareholders, investors, employees and business partners.

Internal regulations

We publish corporate regulations on our website: Corporate Governance Documents. The regulations specify the principles of cooperation between the company's bodies, employees and shareholders. We operate in accordance with applicable legal norms and industry standards.

Intellectual property

We respect the intellectual property rights of other entities and actively protect our patents. Transparent management of intellectual property increases the value of our projects and strengthens our market credibility.

Ownership and supervisory structure

Our supervisory board operates independently of the management board, which ensures appropriate control and supervision over the company's activities. The shareholder structure is dispersed, which promotes transparency and balance in decision-making.

Research quality

We ensure high quality of scientific research, based on international standards and independent verification. Our goal is to provide reliable and credible results that are the basis for further development of our therapies.

Shareholder Relations

We maintain an ongoing dialogue with shareholders, providing them with regular and transparent access to information on the company's activities. Regular reports and meetings allow shareholders to closely monitor the company's development.

♻️ Environmental Issues (E)

We operate in a responsible manner towards the natural environment, taking into account the specifics of our industry and available resources.

Waste management

We cooperate with specialized companies dealing with the safe disposal of laboratory waste, ensuring that the impact of our activities on the environment is minimized.

Animal testing

We conduct animal testing only when it is necessary for the further development of our therapies. We use the services of verified, certified entities, ensuring full compliance with applicable ethical and legal standards.

Greenhouse gas emissions

Our activities generate limited direct emissions. Indirect emissions arise during cooperation with laboratories, suppliers and in the functioning of the office. We are involved in the search for solutions that reduce our impact on the environment.

Measurement and reporting

We conduct environmental measurements to the extent required by law and adequate to the profile of our activities. Among other things, we measure the amount of toxic waste, but we do not measure indirect emissions, which are more difficult to estimate in our industry.

Environmental risks

The biotechnology industry in which we operate is characterized by low exposure to risks related to climate change and biodiversity loss. Nevertheless, we monitor these risks and implement appropriate procedures to minimize the risks related to our business activities.

Our ESG strategy reflects our ambition not only to discover life-saving therapies, but also to do so in a responsible, ethical and sustainable manner. As we develop our company, we will evolve and adapt our activities in line with stakeholder expectations and global ESG standards.